Insulet (NASDAQ:PODD) Releases Earnings Results, Beats Estimates By $0.40 EPS

Key Points

• Insulet reported quarterly EPS of $1.99, beating estimates of $1.59, while revenue rose about 19% year over year to $842 million, above forecasts.
• The company raised its 2026 outlook to the high end of its prior range, projecting 21%–22% constant-currency revenue growth and more than 30% adjusted EPS growth. However, it expects 2027 revenue growth to fall modestly below its previous mid-teens framework.
• Insulet’s board authorized an additional $1 billion share repurchase, including $400 million planned for the fourth quarter.

Insulet (NASDAQ:PODD - Get Free Report) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $1.99 EPS for the quarter, beating the consensus estimate of $1.59 by $0.40, FiscalAI reports. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. During the same quarter in the prior year, the firm earned $1.24 EPS. Insulet's revenue for the quarter was up 19.2% on a year-over-year basis.

Here are the key takeaways from Insulet's conference call:

• Third-quarter revenue rose 19.6% in constant currency to $842 million, supported by more than 20% growth in the global customer base. Adjusted operating margin expanded 490 basis points, and adjusted EPS increased 60% year over year.
• Insulet raised its 2026 outlook to the high end of its prior range, expecting 21%–22% constant-currency revenue growth and more than 30% adjusted EPS growth. It also expects approximately 150 basis points of adjusted operating margin expansion.
• Management expects 2027 revenue growth to be modestly below its prior mid-teens framework, with U.S. growth toward the lower end of its earlier range and international growth moderating meaningfully. The company cited tougher comparisons, less international price-mix benefit, new competition, and limited near-term contributions from launches.
• Insulet reported modest improvement in type 2 customer retention after changes to sampling, onboarding, sales incentives, and customer support. Its Omnipod Discover platform has been adopted by more than 35,000 users and 5,000 clinicians, though management said the impact of these efforts will build over time.
• The board approved a $1 billion increase to the share repurchase authorization, with $400 million planned for repurchases in the fourth quarter using cash on hand.

Insulet Stock Performance

Insulet stock traded up $5.63 during trading hours on Wednesday, reaching $160.49. 1,369,811 shares of the stock were exchanged, compared to its average volume of 1,392,058. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The stock has a market cap of $11.13 billion, a P/E ratio of 30.00, a P/E/G ratio of 1.21 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The firm's 50 day moving average is $141.21 and its 200 day moving average is $178.61.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PODD. JPMorgan Chase & Co. lowered shares of Insulet from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $275.00 to $152.00 in a research note on Thursday, August 6th. Royal Bank Of Canada decreased their target price on shares of Insulet from $245.00 to $160.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Oppenheimer lowered Insulet from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Canaccord Genuity Group dropped their price target on Insulet from $249.00 to $179.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Insulet in a research note on Monday, September 21st. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $186.68.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted earnings of $1.99 per share, topping the $1.59 consensus estimate. Revenue increased 19.2% year over year to $842 million, also ahead of expectations, with reports citing stronger net income and margin expansion. Insulet Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company announced a $1 billion share buyback, which could support demand for shares and signals management’s willingness to return capital to investors. Insulet announces $1 billion equity buyback
• Neutral Sentiment: Insulet maintained its 2026 EPS outlook, providing continuity but no increase to the earnings forecast in the cited report. Insulet Q3 adjusted earnings, revenue rise; 2026 EPS outlook maintained

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.